Immunology and Immunotherapy of Head and Neck Cancer
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
The immune system plays a key role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. HNSCC cells evade the host immune system through manipulation of their own immunogenicity, production of immunosuppressive mediators, and promotion of immunomodulatory cell types. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides a brief overview of key components of the immune infiltrating cells in the tumor microenvironment, reviewing immunological principles related to head and neck cancer, including the concept of cancer immunosurveillance and immune escape. Current immunotherapeutic strategies and emerging results from ongoing clinical trials are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“A moAb against CTLA-4, ipilimumab, was the first drug in this class to demonstrate clinical benefit and was approved by the US Food and Drug Administration for patients with metastatic melanoma.(86) Tremelimumab is also available for CLTA-4 targeting.”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Impairment of tumor-infiltrating T lymphocytes has also been reported in HNSCC and other cancers,(8,9) with a strong impact on clinical outcome.(10) In addition, suppressive regulatory T cells (Tregs) have been linked to HNSCC tumor progression.”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“The discovery of interferon-gamma (IFN- ) and its proapoptotic effect on tumor growth gave additional supportto the potential for immune clearance of cancer cells.(13,14) Mice with genetically induced immunodeficiency were found to be more susceptible to both spontaneous and chemically induced tumors.”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationThe molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Self-citationCohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Self-citationSteuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
The Multidisciplinary Team (MDT) Approach and Quality of Care
Taberna, M., Gil Moncayo, F., Jané-Salas, E., Antonio, M., Arribas, L., Vilajosana, E., Peralvez Torres, E., & Mesía, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00085 · Cited by 513
Solomon, B., Young, R. J., & Rischin, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.008 · Cited by 467
Human papillomavirus-related oropharyngeal cancer
Taberna, M., Mena, M., Pavón, M. A., Alemany, L., Gillison, M. L., & Mesía, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx304 · Cited by 399
Human papillomavirus as a driver of head and neck cancers
Sabatini, M. E., & Chiocca, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0602-7 · Cited by 387
Ludwig, S., Floros, T., Theodoraki, M.-N., Hong, C.-S., Jackson, E. K., Lang, S., & Whiteside, T. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2819 · Cited by 334
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
Elmusrati, A., Wang, J., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 312
Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L. P., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 306
Self-citationImmunotherapy for head and neck cancer: Recent advances and future directions
Cramer, J. D., Burtness, B., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104460 · Cited by 302
Self-citationFrameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P., Cavanaugh, M., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 275
Zhou, L., Mudianto, T., Ma, X., Riley, R., & Uppaluri, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1351 · Cited by 269
“Deficiency in the expression of HLA class I components, including B2M and specific HLA alleles, and antigen-processing machinery have been correlated with poor prognosis of HNSCC (16, 17).”
BackgroundImmune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
Mei, Z., Huang, J., Qiao, B., & Lam, A. K.-Y. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0084-8 · Cited by 257
Kim, H. R., Ha, S.-J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., Kim, E. K., Pyo, K. H., Jung, I., Seo, D., et al. (2016) · Scientific Reports · doi:10.1038/srep36956 · Cited by 256
Kitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010240 · Cited by 256
Rosewell Shaw, A., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M. K., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 219
PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
Concha-Benavente, F., Kansy, B., Moskovitz, J., Moy, J., Chandran, U., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 161
“Cancer Immunol Res; 6(12) December 2018 Cancer Immunology Research 1550”
BackgroundSelf-citationLiang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72
Mao, L., Xiao, Y., Yang, Q.-C., Yang, S.-C., Yang, L.-L., & Sun, Z.-J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105472 · Cited by 68
Cho, J. H., & Lim, Y. C. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105084 · Cited by 27
The biology of combination immunotherapy in recurrent metastatic head and neck cancer
Yuan, X., Yi, M., Zhang, W., Xu, L., Chu, Q., Luo, S., & Wu, K. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106002 · Cited by 13
Metadata
- Authors
- Ferris, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-10
- Volume
- 33
- Issue
- 29
- Pages
- 3293-3304
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163814058
- Cited by
- 668
- References
- 99
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.